A cost analysis of alternative treatments for duodenal ulcer

Thomas Imperiale, T. Speroff, R. D. Cebul, A. J. McCullough

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Objective: To compare the costs of alternative strategies for the treatment of duodenal ulcer. Design: A cost comparison using decision analysis. Methods: A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies: 1) H2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H2-receptor antagonist therapy, and 3) urease test-based treatment. For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure. The cohort modeled for this analysis consisted of patients at low risk for a malignant ulcer. Probability estimates were derived from published clinical trials, cohort studies, and expert opinion. Side effects from combination therapy with antibiotics and H2-receptor antagonists and resulting costs were included from the perspective of a group practice model health maintenance organization. Results: For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 86% to 76%; the costs ranged from $284 for secondary (re)treatment with empiric antibiotic and H2-receptor antagonist therapy to $398 for endoscopy-guided secondary treatment. Initial treatment with an H2-receptor antagonist resulted in the highest costs, ranging from $372 for secondary treatment with empiric antibiotic and H2- receptor antagonist therapy to $679 for endoscopy-guided secondary treatment. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori. Conclusions: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure. These cost savings and the lower recurrence rates associated with this treatment favor eradication of H. pylori as part of the initial treatment of duodenal ulcer.

Original languageEnglish (US)
Pages (from-to)665-672
Number of pages8
JournalAnnals of Internal Medicine
Volume123
Issue number9
StatePublished - 1995
Externally publishedYes

Fingerprint

Duodenal Ulcer
Costs and Cost Analysis
Histamine H2 Receptors
Therapeutics
Helicobacter pylori
Helicobacter Infections
Anti-Bacterial Agents
Endoscopy
Recurrence
Urease
Ulcer
Cohort Studies
Group Practice
Retreatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Imperiale, T., Speroff, T., Cebul, R. D., & McCullough, A. J. (1995). A cost analysis of alternative treatments for duodenal ulcer. Annals of Internal Medicine, 123(9), 665-672.

A cost analysis of alternative treatments for duodenal ulcer. / Imperiale, Thomas; Speroff, T.; Cebul, R. D.; McCullough, A. J.

In: Annals of Internal Medicine, Vol. 123, No. 9, 1995, p. 665-672.

Research output: Contribution to journalArticle

Imperiale, T, Speroff, T, Cebul, RD & McCullough, AJ 1995, 'A cost analysis of alternative treatments for duodenal ulcer', Annals of Internal Medicine, vol. 123, no. 9, pp. 665-672.
Imperiale, Thomas ; Speroff, T. ; Cebul, R. D. ; McCullough, A. J. / A cost analysis of alternative treatments for duodenal ulcer. In: Annals of Internal Medicine. 1995 ; Vol. 123, No. 9. pp. 665-672.
@article{e72f4afa97d44799b0b6d8ee39f7e9af,
title = "A cost analysis of alternative treatments for duodenal ulcer",
abstract = "Objective: To compare the costs of alternative strategies for the treatment of duodenal ulcer. Design: A cost comparison using decision analysis. Methods: A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies: 1) H2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H2-receptor antagonist therapy, and 3) urease test-based treatment. For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure. The cohort modeled for this analysis consisted of patients at low risk for a malignant ulcer. Probability estimates were derived from published clinical trials, cohort studies, and expert opinion. Side effects from combination therapy with antibiotics and H2-receptor antagonists and resulting costs were included from the perspective of a group practice model health maintenance organization. Results: For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 86{\%} to 76{\%}; the costs ranged from $284 for secondary (re)treatment with empiric antibiotic and H2-receptor antagonist therapy to $398 for endoscopy-guided secondary treatment. Initial treatment with an H2-receptor antagonist resulted in the highest costs, ranging from $372 for secondary treatment with empiric antibiotic and H2- receptor antagonist therapy to $679 for endoscopy-guided secondary treatment. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori. Conclusions: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure. These cost savings and the lower recurrence rates associated with this treatment favor eradication of H. pylori as part of the initial treatment of duodenal ulcer.",
author = "Thomas Imperiale and T. Speroff and Cebul, {R. D.} and McCullough, {A. J.}",
year = "1995",
language = "English (US)",
volume = "123",
pages = "665--672",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - A cost analysis of alternative treatments for duodenal ulcer

AU - Imperiale, Thomas

AU - Speroff, T.

AU - Cebul, R. D.

AU - McCullough, A. J.

PY - 1995

Y1 - 1995

N2 - Objective: To compare the costs of alternative strategies for the treatment of duodenal ulcer. Design: A cost comparison using decision analysis. Methods: A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies: 1) H2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H2-receptor antagonist therapy, and 3) urease test-based treatment. For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure. The cohort modeled for this analysis consisted of patients at low risk for a malignant ulcer. Probability estimates were derived from published clinical trials, cohort studies, and expert opinion. Side effects from combination therapy with antibiotics and H2-receptor antagonists and resulting costs were included from the perspective of a group practice model health maintenance organization. Results: For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 86% to 76%; the costs ranged from $284 for secondary (re)treatment with empiric antibiotic and H2-receptor antagonist therapy to $398 for endoscopy-guided secondary treatment. Initial treatment with an H2-receptor antagonist resulted in the highest costs, ranging from $372 for secondary treatment with empiric antibiotic and H2- receptor antagonist therapy to $679 for endoscopy-guided secondary treatment. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori. Conclusions: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure. These cost savings and the lower recurrence rates associated with this treatment favor eradication of H. pylori as part of the initial treatment of duodenal ulcer.

AB - Objective: To compare the costs of alternative strategies for the treatment of duodenal ulcer. Design: A cost comparison using decision analysis. Methods: A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies: 1) H2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H2-receptor antagonist therapy, and 3) urease test-based treatment. For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure. The cohort modeled for this analysis consisted of patients at low risk for a malignant ulcer. Probability estimates were derived from published clinical trials, cohort studies, and expert opinion. Side effects from combination therapy with antibiotics and H2-receptor antagonists and resulting costs were included from the perspective of a group practice model health maintenance organization. Results: For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 86% to 76%; the costs ranged from $284 for secondary (re)treatment with empiric antibiotic and H2-receptor antagonist therapy to $398 for endoscopy-guided secondary treatment. Initial treatment with an H2-receptor antagonist resulted in the highest costs, ranging from $372 for secondary treatment with empiric antibiotic and H2- receptor antagonist therapy to $679 for endoscopy-guided secondary treatment. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori. Conclusions: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure. These cost savings and the lower recurrence rates associated with this treatment favor eradication of H. pylori as part of the initial treatment of duodenal ulcer.

UR - http://www.scopus.com/inward/record.url?scp=0028806610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028806610&partnerID=8YFLogxK

M3 - Article

C2 - 7574221

AN - SCOPUS:0028806610

VL - 123

SP - 665

EP - 672

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -